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Summary
To determine the role of the phosphatidylinositol 3-kinase (PI3-K) pathway in pancreas development, we generated a
pancreas-specific knockout of Pten, a negative regulator of PI3-K signaling. Knockout mice display progressive replace-
ment of the acinar pancreas with highly proliferative ductal structures that contain abundant mucins and express Pdx1
and Hes1, two markers of pancreatic progenitor cells. Moreover, a fraction of these mice develop ductal malignancy. We
provide evidence that ductal metaplasia results from the expansion of centroacinar cells rather than transdifferentiation
of acinar cells. These results indicate that Pten actively maintains the balance between different cell types in the adult
pancreas and that misregulation of the PI3-K pathway in centroacinar cells may contribute to the initiation of pancreatic
carcinoma in vivo.S I G N I F I C A N C E
Metaplasia—the replacement of one adult tissue type with another—is a harbinger of cancer in many tissues. It is unknown whether
metaplastic cells arise by transdifferentiation or through the expansion of a minority cell type or a stem/progenitor cell. Pancreas-
specific deletion of Pten has provided an unanticipated and informative view of this process by revealing a progressive ductal
metaplastic process with infrequent malignant transformation. Molecular and histopathological analysis supports the view that ex-
pansion of centroacinar cells, rather than transdifferentiation of acinar cells, is the mechanism for metaplasia in this model. These
results fortify the link between PI3-K signaling and pancreatic cancer and suggest that PI3-K may act by perturbing the balance
between cell types in the adult pancreas.Introduction
Pancreatic adenocarcinoma is among the most lethal human
tumors, killing approximately 95% of patients within 5 years of
diagnosis. Recent work has led to important advances in the
understanding of pancreatic cancer biology. First, histologic
evaluation of resected pancreatic adenocarcinomas has facili-
tated the morphologic classification of dysplastic lesions that
represent the putative precursors of invasive carcinoma—pan-
creatic intraepithelial neoplasia (PanIN) and intraductal papillary
mucinous neoplasia (IPMN). PanINs encompass a spectrum of
pancreatic ductal epithelial changes characterized by en-
hanced mucin production, graded nuclear atypia, and loss of
cell polarity (Hruban et al., 2001); IPMNs constitute another
class of noninvasive precursor lesions that are histologicallyCANCER CELL : SEPTEMBER 2005 · VOL. 8 · COPYRIGHT © 2005 ELSEVIEdistinct from, but related to, PanINs (Hruban et al., 2004). Sec-
ond, molecular genetic analysis has implicated several genes
in the progression of pancreatic carcinoma: these include the
Kras, INK4A/ARF, and p53 genes, as well as elements of the
EGF, TGFβ, Notch, and hedgehog signaling pathways (Jaffee
et al., 2002; Miyamoto et al., 2003; Thayer et al., 2003). Third,
several animal models of pancreatic cancer have been devel-
oped. Implantation of the carcinogen dimethylbenzanthracene
(DMBA; Dissin et al., 1975) or overexpression of TGFα in exo-
crine tissue (Sandgren et al., 1990; Jhappan et al., 1990)
causes a premalignant acinar-to-ductal metaplasia by a pro-
cess that has been generally regarded to be transdifferentiation
(Wagner et al., 1998, 2001; Schmid, 2002; Bockman et al.,
2003). Newer models that incorporate the most frequent ge-
netic alteration in human pancreatic cancer—an activated mu-R INC. DOI 10.1016/j.ccr.2005.07.015 185
A R T I C L Etant Kras allele—faithfully reproduce the histologic features of
invasive human disease (Hingorani et al., 2003; Aguirre et al.,
2003).
In spite of this progress, critical gaps remain in our under-
standing of pancreatic cancer. On the molecular level, the in-
terplay between different signaling pathways remains an area
of active investigation. On the tissue level, the cell type that
gives rise to ductal adenocarcinoma is not known. Proposed
cellular origins for pancreatic carcinoma include duct cells
(Cubilla and Fitzgerald, 1976; Hruban et al., 2001), acinar cells
(Meszoely et al., 2001; Wagner et al., 2001; Bockman et al.,
2003), islet cells (Yoshida and Hanahan, 1994; Pour et al., 2003),
or rare undifferentiated precursor cells in the adult pancreas
(Leach, 2004). Centroacinar cells have emerged as a candidate
cell of origin based upon the persistent activation of the Notch
pathway in these cells in adulthood (Miyamoto et al., 2003).
Although centroacinar cells constitute the terminal cells of the
ductal system and contain ultrastructural features of ductal
cells (Ekholm et al., 1962), the precise lineage of centroacinar
cells has not yet been elucidated.
The Pten tumor suppressor gene encodes a dual activity
phosphatase that is frequently mutated in human tumors (Luo et
al., 2003). As an antagonist of the phosphatidylinositol 3-kinase
(PI3-K) signaling pathway, Pten occupies a central position in
the response to signals from growth factor receptors governing
cell proliferation and survival, among other biological pro-
cesses. While point mutations in Pten occur rarely in pancreatic
cancer (Sakurada et al., 1997; Okami et al., 1998), functional
inactivation of PTEN through promoter methylation (Asano et
al., 2004), loss of protein expression (Altomare et al., 2003),
reduction of mRNA levels (Ebert et al., 2002), or loss of hetero-
zygosity (LOH) of linked markers (Hahn et al., 1995; Okami et
al., 1998) occurs with high frequency. Studies in pancreatic
cancer cell lines have demonstrated that PI3-K signaling is re-
quired for growth and survival of tumor cells (Perugini et al.,
2000; Shah et al., 2001; Bondar et al., 2002). Furthermore, am-
plification or activation of AKT2 kinase, a major target of the
PI3-K complex, occurs in up to 60% of pancreatic cancers
(Cheng et al., 1996; Ruggeri et al., 1998; Altomare et al., 2003;
Schlieman et al., 2003), supporting the participation of an acti-
vated PI3-K-AKT axis in this disease. Nevertheless, the role
of activated PI3-K signaling in the initiation or progression of
pancreatic carcinoma in vivo has not been evaluated on the
genetic level.
Here, to study the biological impact of pancreatic PI3-K acti-
vation, we examined the consequences of pancreas-specific
Pten gene deletion. Serial analyses revealed progressive pan-
creatic abnormalities, with the gradual replacement of the en-
tire exocrine pancreas with ductal structures lined by mucin-
producing epithelium, and eventual tumor formation. This
mouse model provides insights into the origin of preneoplastic
metaplasia in the pancreas.
Results
Generation of mice with pancreas-specific Pten deletion
Immunohistochemistry was performed to determine the normal
expression pattern of PTEN in the pancreas. In agreement with
a previous report (Perren et al., 2000), strong PTEN staining
was observed in the pancreatic ducts and islets, but not acinar186cells (Figures 1A, 1B, and 1D and data not shown). In addition,
PTEN staining was observed in cells that occupied the distinc-
tive centroacinar position (Figure 1B, arrowhead and inset).
Mice carrying a “floxed” allele of the Pten gene (Groszer et
al., 2001) were bred to Pdx1-Cre transgenic mice (Gu et al.,
2002). Compound Pdx1-Cre;Ptenlox/lox mice were born at the
expected Mendelian ratio and exhibited normal growth and de-
velopment through weaning. Deletion of the Pten gene within
the pancreas was confirmed by several methods. Cre activity
was confirmed by crossing mice from the Z/AP reporter strain
(Lobe et al., 1999) into the Pdx1-Cre;Ptenlox/lox background. As
reported previously (Gu et al., 2002), widespread expression of
human placental alkaline phosphatase (HPAP)—reflecting exci-
sion of a transcriptional stop sequence in the Z/AP trans-
gene—was observed in all pancreatic lineages of adult mice
(Figure 1C). Pancreas-specific deletion of Pten was confirmed
by PCR for the recombined allele (Figure 6A and data not
shown). Next, immunohistochemistry for PTEN and phospho-
AKT (P-AKT) was performed. As expected, PTEN staining was
lost in ducts of Pdx1-Cre;Ptenlox/lox mice (Figure 1E). The AKT
kinase lies downstream of PI3-K, and its phosphorylation
status reflects the activity of the PI3-K pathway. Pdx1-Cre;
Ptenlox/lox but not wild-type ducts exhibited strong P-AKT
staining, reflecting kinase activation (Figures 1D and 1E). Fi-
nally, cytoplasmic redistribution of the forkhead transcription
factor FKHR reflects active PI3-K/AKT signaling (Brunet et al.,
1999). In contrast to nuclear staining in wild-type, cytoplasmic
staining was observed in duct cells of Pten-deficient mice (see
Figure S4 in the Supplemental Data available with this article
online). We infer that Pten was deleted in all pancreatic lineages
with resulting constitutive activation of the PI3-K pathway in
compartments that normally express Pten, namely islets,
ducts, and centroacinar cells.
Pancreatic PTEN deficiency causes an islet phenotype
and early expansion of the ductal lineage
The pancreata of newborn Pdx1-Cre;Ptenlox/lox mice appeared
normal upon gross inspection. However, knockout mice dis-
played abnormal endocrine development, marked by the variable
appearance of enlarged and irregularly shaped islets (Figures 1F
and 1G). These abnormalities in islet morphogenesis did not
translate into dysregulated glucose homeostasis, as fed and
fasting blood glucose levels and glucose tolerance were iden-
tical in Ptenlox/lox and Pdx1-Cre;Ptenlox/lox mice (Figure 1H and
data not shown). With the exception of this islet phenotype,
pancreata from newborn Pdx1-Cre;Ptenlox/lox mice appeared
histologically normal.
BrdU labeling was performed to determine whether Pten de-
ficiency alters the proliferation rate in either islets or ducts. Pre-
weaned Pdx1-Cre;Ptenlox/lox mice exhibited an approximately
4-fold increase in BrdU incorporation in the acinar pancreas
(Figure 2A, lower panels, and data not shown), in areas that
were otherwise histologically normal (Figure 2A, upper panels).
Closer examination of the BrdU staining pattern revealed that a
sizeable fraction of the labeled cells occupied the centroacinar
position (Figure 2A, inset). A smaller and more variable en-
hancement of BrdU incorporation was detected in histologi-
cally normal epithelial cells present within large ducts (Figures
S1A and S1B); large ducts appeared otherwise normal (data
not shown).
We assessed the ductal lineage with the lectin DolichosCANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 1. Expression and deletion of Pten in the pancreas
A and B: Expression of PTEN in pancreatic duct cells (A), islet cells (left por-
tion of B), and a centroacinar cell (arrowhead; 800×). Centroacinar cells
were also visualized with Nomarski optics (inset).
C: Evidence for Cre-mediated deletion in the pancreas. Sections of the
pancreas from a Pdx1-Cre;Ptenlox/lox; Z/AP mouse, stained for human pla-
cental alkaline phosphatase (HPAP; dark blue) and counterstained with
hematoxylin (pale blue). HPAP expression, reflecting recombination in the
Z/AP locus, is seen in acini (arrowhead) and ducts (arrow). The HPAP repor-
ter protein is localized to apical membranes in acinar cells (400×).
D and E: Expression of PTEN (red) and phospho-AKT (green) in the pancreas
of wild-type (D) and Pdx1-Cre;Ptenlox/lox (E) littermates at 4 weeks of age.
Nuclei are stained pale blue with DAPI. Arrows point to ductal epithelium.
Note PTEN expression in wild-type ducts and scattered mesenchymal cells,
but not in acinar tissue (cells in top half of D). PTEN expression persists in
mesenchymal tissue surrounding the ducts in the mutant (scattered non-
epithelial red-staining cells; 400×).
F and G: Pancreatic Pten deficiency causes islet hyperplasia. Immunofluo-
rescence staining of insulin (green) and glucagon (red) in typical islets from
the pancreas of Ptenlox/lox (F) and Pdx1-Cre;Ptenlox/lox (G) littermates.
H: Glucose tolerance test on Ptenlox/lox and Pdx1-Cre;Ptenlox/lox littermates
(age 2 months). Despite an abnormal islet morphology, Pdx1-Cre;Ptenlox/lox
mice responded normally to a glucose challenge.CANCER CELL : SEPTEMBER 2005Figure 2. Increased proliferation and centroacinar cell expansion in Pten-
deleted pancreata
A: Pdx1-Cre;Ptenlox/lox mice exhibit increased proliferation in the acinar
compartment. Mice were injected with BrdU 2 hr prior to sacrifice. Pdx1-
Cre;Ptenlox/lox mice (Pten KO) had an increased number of BrdU+ cells
(brown) compared to Ptenlox/lox (WT) littermates (lower panels), despite
normal acinar and ductal H&E staining (upper panels; 200×). BrdU+ cells
tended to occupy a centroacinar position in Pdx1-Cre;Ptenlox/lox mice (in-
set; 400×).
B: Pdx1-Cre;Ptenlox/lox mice exhibit enhanced ductal staining with the lec-
tin DBA. Upper panels: DBA lectin staining of 3-week-old mice (brown)
showing enhancement of ductal and centroacinar (arrowheads) staining
in Pdx1-Cre;Ptenlox/lox (Pten KO) mice (160×). Lower panels: E17.5 embryos
stained with DBA lectin (red) and DAPI (blue), also demonstrating en-
hanced staining in Pten KO embryos (100×).
C: Electron micrographs demonstrating an increase in centroacinar cells
in Pdx1-Cre;Ptenlox/lox mice (KO) compared to Ptenlox/lox mice (WT).
Centroacinar cells (arrowheads) are surrounded by zymogen-rich acinar
cells (Z), with which they share a lumen (asterisks; 2,950×). The basal body
of a cilium (boxed area) is shown (inset; 11,500×).biflorus agglutinin (DBA), a marker of ductal cells and some
pancreatic progenitor cells (Murtaugh et al., 2003). In wild-type
pancreas, DBA staining was evident in interlobular and intra-
lobular pancreatic ducts. DBA-labeled cells were also present
in acinar regions, where staining was again observed in a
centroacinar pattern (Figure 2B, upper left). Pdx1-Cre;Ptenlox/lox
mice displayed a dramatic expansion in DBA staining through-
out the exocrine pancreas (Figure 2B, upper right). This increase
in DBA staining was first apparent during embryogenesis, with
a significant expansion of the DBA-positive population as early
as E17.0 (Figure 2B, lower panels). The area stained by DBA in
Pdx1-Cre;Ptenlox/+ and Pdx1-Cre;Ptenlox/lox embryos occupied
3.2% ± 1.3% and 7.7% ± 3.7% of the tissue, respectively
(p = 0.0003).187
A R T I C L EThe pattern of increased BrdU and DBA staining raised the
possibility that pancreatic centroacinar cells were affected by
Pten deletion. To look directly at the centroacinar cell compart-
ment, we analyzed pancreata from wild-type and Pdx1-Cre;
Ptenlox/lox mice by electron microscopy. In wild-type mice,
centroacinar cells were found by carefully screening pancreas
sections. As described previously (Ekholm et al., 1962), these
cells were smaller than acinar cells and had a low cytoplasmic
density with sparse endoplasmic reticulum (Figure 2C). Centro-
acinar cells were found in much greater abundance in Pdx1-
Cre;Ptenlox/lox pancreata and were present in groups of four to
eight cells, contrasting dramatically with the appearance of single
or doublet centroacinar cells in wild-type pancreata. Some of the
centroacinar cells in mutant animals contained cilia, confirming a
duct-like phenotype (Figure 2C, inset). Thus, islet hyperplasia and
expansion of DBA+ centroacinar cells precede other phenotypes
associated with Pten deficiency.
Ductal metaplasia and carcinoma
in Pten-deficient pancreata
To determine whether Pten deficiency results in age-depen-
dent phenotypes, a cohort of Pdx1-Cre;Ptenlox/lox mice and
age-matched littermate controls was followed into adulthood.
Starting at approximately 3 weeks of age, mutant pancreata ex-
hibited multifocal architectural changes. The basic lesion con-
sisted of a ductular metaplasia of the acini, with neoductules sur-
rounded by loose spindle mesenchyme (Figure 3A). Examination
under high magnification revealed the presence of structures con-
taining both acinar and ductular cells, suggestive of an active
metaplastic transition (Figure 3B, arrow). Acini in early stages of
the transition exhibited localized expansion of small cells, con-
tinuous with an enlarged acinar lumen (Figure 3B, arrowheads).
More advanced metaplastic lesions exhibited a lobular distribu-
tion, with lobules exhibiting metaplasia positioned adjacent to
lobules that appeared preserved (Figure 3C). These pancreata ex-
hibited extensive ductular complexes that completely replaced
the acinar parenchyma but spared the endocrine islets (Fig-
ure 3D).
Because Pdx1 promoter activity is largely confined to the islets
of adult pancreas (Figure 4B), recombination in other compart-
ments of the pancreas was likely to have occurred during em-
bryonic development. To further test this, Pdx1-CreERTM;
Ptenlox/lox mice (Gu et al., 2002) were injected with tamoxifen
(TM) at 2–3 weeks of age and examined 8–10 weeks later
(n = 10 mice). These mice exhibited islet hyperplasia but no
ductal abnormalities or increase in DBA staining (data not
shown), suggesting that the ductal phenotype in Pdx1-Cre;
Ptenlox/lox mice is caused by embryonic Pten loss.
At approximately 2–3 months of age, Pdx1-Cre;Ptenlox/lox
mice began to show signs of illness, with wasting, respiratory
distress, and frequent death before 6 months of age. Necropsy
of several animals revealed the presence of a cystic mass oc-
cupying the pancreatic space. Histologically, some tubular
complexes took on a cystic appearance (Figure 3E, asterisks)
and exhibited mucinous metaplasia (Figure 3F). An inflamma-
tory infiltrate with extension of inflammation into the ductular
epithelium was noted in some samples.
Malignant transformation was observed in two Pdx1-Cre;
Ptenlox/lox animals (out of 14 adult mice that were examined
histologically), both of which exhibited bloody ascites and a
firm pancreatic mass. In one 11-week-old animal malignant188Figure 3. Pten deficiency leads to progressive ductal metaplasia and ma-
lignant transformation
A: Pdx1-Cre;Ptenlox/lox pancreas, 4 weeks. A zone of transition is seen, with
diffuse metaplasia of acinar tissue to a ductal phenotype (160×).
B: High-magnification view from A. Structures having both acinar (arrow)
and ductal features are readily seen. Some acini display an increased
number of small cells in continuity with an enlarged acinar lumen (arrow-
heads; 640×).
C: Pdx1-Cre;Ptenlox/lox pancreas, 17 weeks. The body of the pancreas has
been replaced by ductal structures (black arrowhead). A few lobules con-
taining normal-appearing acinar parenchyma remain intact (white arrow-
head; 20×).
D: Magnified view of the boxed area in C. A lobule that has undergone
metaplastic transformation is shown adjacent to normal acinar tissue. An
islet within the metaplastic region appears normal (arrow; 100×).
E: Pdx1-Cre;Ptenlox/lox pancreas, 11 weeks, showing cystic dilation of neo-
ductules (asterisks). A hyalinized stroma is visible between the ducts (100×).
F:Magnified view of boxed area in E showing tall mucin-producing epithe-
lial cells within the neoductules (400×).
G: Papillary ductal adenocarcinoma arising in an 11-week-old Pdx1-Cre;
Ptenlox/lox animal. The ductal epithelium is characterized by proliferative
epithelial fronts (100×).
H: Duodenum invaded by adjacent pancreatic ductal adenocarcinoma.
The duodenal lamina propria is replaced by well-differentiated pancreatic
adenocarcinoma (dashed line) that has invaded through the muscularis
mucosae (arrowhead). The villous duodenal surface (lu) is preserved
(100×).transformation to a papillary ductal adenocarcinoma was ob-
served; the tumor contained exuberant micropapillary projec-
tions, with marked nuclear atypia, mitoses, and apoptosis (Fig-
ure 3G). The tumor stained with antibodies that recognize the
mucin Muc5AC, and some areas exhibited small glandular
crowding that was suspicious for invasion (Figure S2 and data
not shown). Regions of continuity were observed between the
mucinous and carcinomatous epithelia (Figure S2), suggesting
that the tumor had arisen directly from the metaplastic epithe-
lium. A second 13-month-old Pdx1-Cre;Ptenlox/lox animal de-
veloped a pancreatic ductal adenocarcinoma that invaded into
the duodenum and exhibited a desmoplastic stroma (Figure 3HCANCER CELL : SEPTEMBER 2005
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plastic epithelium
A: Wild-type (WT; left) or Pdx1-Cre;Ptenlox/lox
(Pten KO; right) pancreata (age 9 to 11 weeks)
stained by the indicated method. Metaplastic
ductules demonstrate loss of amylase expres-
sion and retention of DBA staining. Alcian blue
reveals abundant acid mucins in the Pten KO
pancreas. Immunohistochemistry for Muc5AC
shows staining in the metaplastic epithelium.
(Muc5AC staining 400×; all others 200×).
B: Pdx1 immunohistochemistry. Left panel: strong
Pdx1 staining in adult wild-type mice is limited to
islets (arrow). Middle panel: Pdx1 is highly ex-
pressed in the metaplastic ductules. Right
panel: structures containing acinar and duct-
like cells demonstrate Pdx1 staining in emerging
ductal elements (arrow); staining intensity in-
creases in more well-formed ductal structures
(arrowhead; 200×).
C: Hes1 immunohistochemistry. Left panel: Hes1
staining is observed in centroacinar cells of
wild-type mice (arrowheads). Middle and right
panels: Hes1 is expressed in the abnormal epi-
thelium of Pdx1-Cre;Ptenlox/lox mice, but not in
adjacent acinar cells (arrow; 400×).and Figure S2). Macrometastatic disease was not observed in
either animal.
A homozygous mutant allele of p53 was introduced into the
Pdx1-Cre;Ptenlox/lox background to determine whether loss of
this tumor suppressor gene altered the spectrum or kinetics of
tumor formation. Two Pdx1-Cre;Ptenlox/lox;p53−/− animals (out
of five examined) developed papillary adenocarcinomas (age 4
and 6 months) that were histologically indistinguishable from
the papillary ductal adenocarcinoma described above (data not
shown). In addition, one (out of five) Pdx1-Cre;Ptenlox/lox;
p53−/− animals developed a small acinar carcinoma (data not
shown).
Features of the metaplastic epithelium
To better understand the mechanism of ductal metaplasia,
pancreata of 9- to 11-week-old Pdx1-Cre;Ptenlox/lox mice were
stained for a variety of markers. Staining was initially performed
for amylase, which marks acinar cells, and the lectin DBA,
which marks centroacinar cells (Figure 2), ductal cells, and em-
bryonic pancreatic progenitor cells. Most of the tubular com-
plexes were positive for DBA and negative for amylase (Figure
4A, upper panels), although numerous structures containing
both acinar and ductal features could be observed (Figures 3B
and 5B). Mucinous metaplasia of the ductal epithelium was
confirmed by Alcian blue staining and ranged from a few cells
to complete ductular replacement; widespread epithelial ex-
pression of Muc5AC (Figure 4A, lower panels) but not Muc2
(data not shown) was observed.
We next examined the mutant epithelium for markers ex-
pressed during pancreatic development, as developmental
programs have been proposed to play a role in pancreatic car-CANCER CELL : SEPTEMBER 2005cinogenesis (Meszoely et al., 2001). The mutant epithelium ex-
pressed Pdx1 (Figure 4B, middle panel), a marker of early fore-
gut and pancreatic progenitor cells (Offield et al., 1996; Gu et
al., 2002) that in the normal adult pancreas is expressed in
islets (Figure 4B, left panel). Areas containing both acini and
neoductules (henceforth referred to as “transitional areas”)
demonstrated low levels of Pdx1 in new duct-like cells and
higher levels of expression in more mature-appearing ductal
structures (Figure 4B, right panel). No increase in Pdx1 staining
was observed in the normal-appearing areas of Pdx1-Cre;
Ptenlox/lox mice (Figure 4B and data not shown). Expression of
the Notch pathway target gene Hes1, another marker of early
pancreatic progenitor cells, was also assessed. Consistent
with prior reports (Miyamoto et al., 2003), Hes1 expression in
normal adult pancreas was limited to centroacinar cells (Figure
4C, left panel) and some duct cells (Figure S3). In contrast,
Hes1 was expressed throughout the mutant epithelium of
Pdx1-Cre;Ptenlox/lox mice (Figure 4C, middle and right panels).
Nkx6.1, another marker of pancreatic progenitors (Hald et al.,
2003), was absent (data not shown).
Although ductal metaplasia was the predominant phenotype
observed in Pdx1-Cre;Ptenlox/lox mice, we also examined
Pdx1-Cre;Ptenlox/lox mice for duct-specific phenotypes. Re-
cently, consensus criteria have been established for “mouse
PanINs” that account for the greater frequency of ductal meta-
plasia in mouse pancreas compared to human. Specifically,
mouse PanINs must meet the cytologic criteria for human
PanINs plus an additional standard—the lesions must arise in
the setting of a preexisting duct and not a metaplastic duct
(R.H. Hruban, N.V. Adsay, J. Albores-Saavedra, M.R. Anver,
A.V. Biankin, G.P. Boivin, E.E. Furth, T. Furukawa, A. Klein, D.S.189
A R T I C L EFigure 5. Analysis of “transitional areas” suggests
that ductal metaplasia occurs by replacement,
rather than transdifferentiation, of acinar cells
A: Epithelial hyperproliferation and acinar cell
death accompany ductal metaplasia. Upper
panels: BrdU staining (gray) demonstrates hy-
perproliferation of metaplastic ductules (Pten
KO; right) compared to wild-type ducts (WT; left)
in mice injected with BrdU 3 hr prior to sacrifice.
Lower panels: TUNEL staining (brown) demon-
strates little or no apoptosis in wild-type pan-
creas (left) and extensive death in an area of
ductal metaplasia in a Pten-deficient pancreas
(right). Substantially less TUNEL staining is ob-
served in the tubular complexes of the mutant
compared to the acini.
B: Transitional areas lack cells that coexpress ac-
inar and ductal markers. During the early stages
of metaplasia, transitional areas with mixed aci-
nar-ductal structures are abundant (see also
Figure 3B). Such structures contain duct-like cells
(DBA-labeled; left) and acinar cells (amylase+;
right) within a tubular complex. Double-stained
sections were analyzed by confocal micro-
scopy (lower panel). Shown are two acini in transition to duct-like epithelium (dashed lines). No cells exhibiting costaining with amylase and DBA were
observed, as would have been predicted if DBA-labeled cells were derived from acinar cells.Klimstra, G. Klöppel, G.Y.L., D.S. Longnecker, J. Lüttges, A.
Maitra, G.J.A. Offerhaus, L. Pérez-Gallego, M. Redston, and
D.A. Tuveson, unpublished data). Two Pdx1-Cre;Ptenlox/lox ani-
mals (out of 14 examined) exhibited ducts with tall mucin-pro-
ducing columnar cells, and a third animal exhibited a more
advanced ductal phenotype characterized by nuclear pseudo-
stratification and atypia (Figure S1). These changes were dis-
tinct from the changes observed in the metaplastic ductules
and occurred in the setting of preexisting ducts. Therefore,
pancreatic deletion of Pten also results in mouse PanINs, even
when the restrictive criteria established by the consensus
panel are utilized.
Metaplasia occurs by replacement,
rather than transdifferentiation
As ductal metaplasia and/or PanIN formation precede pancre-
atic carcinogenesis, we sought to determine the cellular origins
of these lesions. We reasoned that metaplasia might occur by
one of two mechanisms: (1) expansion of a ductal lineage cell
with parallel acinar cell loss, or (2) transdifferentiation of acinar
cells into ductal cells, as proposed previously (Wagner et al.,
1998; Schmid et al., 1999). We performed several experiments
to distinguish between these two mechanisms. If metaplasia
occurs through expansion and replacement, we would predict
that cellular proliferation would be detectable prior to histologic
changes, and that increased cell death would accompany the
loss of acinar tissue. In accordance with this model, BrdU la-
beling of young Pdx1-Cre;Ptenlox/lox mice had demonstrated
that centroacinar cells are highly proliferative before the onset
of metaplasia (Figure 2A). This hyperproliferative state was
present at an even greater level following metaplastic changes
(Figure 5A, upper panels). Furthermore, TUNEL staining of
Pdx1-Cre;Ptenlox/lox pancreata revealed a significant increase
in the apoptosis of acinar cells in transitional areas (Figure 5A,
bottom panels). Amylase/TUNEL coimmunostaining revealed
the presence of numerous double-positive cells within the lu-190mens of the neoductules, suggesting that acinar cell bodies
had been deposited into the lumen (data not shown).
One prediction of an acinar-to-ductal transdifferentiation
model is that intermediate cell types should be detectable. We
focused our search on transitional areas, in which structures
containing both ductal and acinar elements had been observed
(Figure 5B, upper panels). Examination of multiple areas by
confocal microscopy failed to reveal any cells that displayed
both amylase immunoreactivity and DBA staining (Figure 5B,
lower panel), and thus we find no evidence for an intermediate
cell type.
Neoductules do not arise from acinar cells
Transdifferentiation and expansion/replacement models for
metaplasia also differ with respect to the cell of origin. A trans-
differentiation model entails a direct conversion from acinar to
ductal fate (Schmid et al., 1999), and thus by definition the cell
of origin would be acinar. By contrast, an expansion/replace-
ment model would entail a nonacinar cell type overtaking the
acinar pancreas. To further test these models, we took advan-
tage of the Cre system to delete Pten in acinar cells.
Transgenic mice were generated in which a cDNA encoding
a tamoxifen (TM)-dependent Cre recombinase (CreERTM; Dan-
ielian et al., 1998; Gu et al., 2002; Dor et al., 2004) was placed
under the control of the elastase gene enhancer (Ornitz et al.,
1987; Swift et al., 1989). Elastase-CreERTM mice were bred
with Z/AP reporter mice to test the acinar specificity of this
deleter strain; upon intraperitoneal injection of the synthetic
estrogen agonist TM, Elastase-CreERTM;Z/AP mice exhibited
widespread HPAP activity in acini but not large ducts or
centroacinar cells (Figure 6 and Figure S6). Further confirm-
ation that the Elastase-CreERTM strain mediates recombination
in acinar (but not centroacinar) cells was achieved by breeding
Elastase-CreERTM mice to Z/EG reporter mice, which express
EGFP in the progeny of cells that have undergone Cre-medi-
ated recombination. Confocal microscopy of TM-injected Elas-CANCER CELL : SEPTEMBER 2005
A R T I C L EFigure 6. Deletion of Pten in acinar cells does not result in ductal metapla-
sia or enhanced DBA staining
A: PCR for the deleted Pten allele (5; product size 300 bp) showing robust
deletion of Pten with the Elastase-CreERTM strain. The following DNA tem-
plates were used. Lanes 1 and 2: pancreas (lane 1) or lung (lane 2) from a
Pdx1-Cre;Ptenlox/lox mouse. Lane 3: pancreas from an Elastase-CreERTM;P-
tenlox/+ pancreas 1 week after three injections with tamoxifen. Lanes 4 and
5: tail DNA from a Ptenlox/D5 (lane 4) or Ptenlox/lox (lane 5) mouse. Lane 6:
no DNA. M, molecular weight standard.
B: Cre-mediated recombination in acinar cells. Staining for human placen-
tal alkaline phosphatase (HPAP) in the pancreas of a 12-week-old Elastase-
CreERTM;Ptenlox/D;Z/AP mouse after a series of tamoxifen (TM) injections.
HPAP is sorted to the apical membrane of acinar cells. Ducts and blood
vessels (bottom half of the image) are not labeled (320×).
C: Normal pancreas histology in Elastase-CreERTM;Ptenlox/D mice at 12
weeks of age, 1 month after TM injection (400×).
D–F: Wild-type (D) and TM-injected Elastase-CreERTM;Ptenlox/D mice (E) dis-
play equivalent levels of DBA lectin staining. For comparison, increased
DBA staining is evident in Pdx1-Cre;Ptenlox/lox mice (F) (200×).tase-CreERTM;Z/EG mice revealed efficient labeling of acinar
cells without evidence for centroacinar cell labeling (Figure S6).
Elastase-CreERTM;Z/AP mice were then bred into the Pten
mutant background, resulting in pancreatic deletion of the Pten
gene (Figure 6A). To achieve more efficient deletion of Pten in
the acinar pancreas, we used mice in which one Pten allele
had already been deleted in the germline (Ptenlox/D; Groszer
et al., 2001). Despite widespread recombination in the acinar
pancreas 4 weeks after multiple TM injections (Figure 6B), Elas-
tase-CreERTM;Ptenlox/D;Z/AP pancreata exhibited no ductal
metaplasia (Figure 6C) and no enhanced staining for DBA com-
pared to wild-type, unlike Pdx1-Cre;Ptenlox/lox pancreata (Fig-
ures 6D–6F). We conclude that ductal metaplasia in Pdx1-Cre;
Ptenlox/lox mice results from the deletion of Pten in a cell type
other than mature acinar cells.
Discussion
In this study, mice with a pancreas-specific deletion of the Pten
gene exhibited widespread ductal metaplasia with increased
mucin production and developed PanIN lesions and malignant
transformation with low frequency. We have examined the pro-
cess of metaplasia in detail and conclude that centroacinar
cells, the terminal cells of the pancreatic ductal system, are
instrumental in initiating the process. These results strengthenCANCER CELL : SEPTEMBER 2005the association between the activation of PI3-K and pancreatic
carcinogenesis and give further insight into the cellular origins
of preneoplastic lesions in the pancreas.
Model for ductal metaplasia
Metaplasia—the widespread interconversion within a tissue of
one cell type into another—is observed in association with can-
cers of the esophagus, stomach, lung, and bladder (Tosh and
Slack, 2002) and has also been reported in association with
pancreatic cancer in both humans and animal models (Parsa
et al., 1985; Bockman et al., 2003). Metaplastic transformation
could occur through one of two mechanisms: transdifferentia-
tion or the expansion of a precursor cell that displaces the nor-
mal tissue. Transdifferentiation has been proposed as a possible
mechanism of metaplasia in transgenic mice that misexpress
TGFα in the exocrine pancreas (Wagner et al., 1998), although
it should be noted that this interpretation was based mainly
on the expression of duct markers by cells within the tubular
complexes. Although we cannot completely exclude the possi-
bility of transdifferentiation in our Pdx1-Cre;Ptenlox/lox model,
we provide evidence of a distinct path to ductal metaplasia
marked by a series of steps that includes centroacinar cell ex-
pansion and acinar cell death (Figure 7).
This model is based on several lines of evidence. First, PTEN
is normally expressed in pancreatic ducts, centroacinar cells,
and islets, but not in acinar cells. As PTEN acts cell autono-
mously to regulate PI3-K function, a loss of function phenotype
is therefore likely to be primarily related to the cell types that
express the gene, namely ductal, centroacinar, and islet cells.
Second, a proliferative expansion of centroacinar cells is seen
prior to any overt histological changes in the pancreas. Third,
“transitional areas” undergoing an apparent acinar-to-ductal
conversion exhibit widespread apoptosis of acinar cells. Fourth,
we failed to find direct evidence of acinar-to-ductal transdifferenti-
ation; no cells coexpressing the ductal marker DBA and exocrine
marker amylase could be found in any of the transitional areas
surveyed. Fifth and finally, Elastase-CreERTM;Ptenlox/D mice, in
which Pten was deleted within acinar cells but not ductal or
centroacinar cells, did not phenocopy the Pdx1-Cre;Ptenlox/lox
phenotype. It is possible that these mice did not exhibit meta-
plasia because Pten deletion was performed postnatally or
because mice were followed for only 1 month. However, Pdx1-
Cre-mediated Pten deletion causes early increases in DBA stain-
ing, which we did not observe in Elastase-CreERTM;Ptenlox/DFigure 7. Model for Pten deletion and ductal metaplasia
Pten-deficient centroacinar cells (green ovals) begin to proliferate during
development. At a few weeks of age, centroacinar cell expansion leads
to apoptosis of acinar cells (white triangles) due to loss of acinar integrity
or survival signals. Progeny of these centroacinar cells form tubular com-
plexes with mucinous metaplasia. See text for details.191
A R T I C L Emice. Taken together, our results indicate that acinar cells are
indifferent to changes in PTEN activity and support replace-
ment rather than transdifferentiation as the mechanism of duc-
tal metaplasia.
Centroacinar cells are very similar to duct cells and exhibit
only subtle differences in apical membrane features (Ekholm et
al., 1962). Such similarities are consistent with centroacinar,
intercalary, and intralobular duct cells all representing a homol-
ogous cell type (Ekholm et al., 1962). Thus, it is reasonable
to postulate that the neoductules detected in Pdx1-Cre;Ptenlox/lox
mice are the direct descendents of this expanded centroacinar
pool (Bardeesy et al., 2002). Supporting this idea, the meta-
plastic epithelium retains expression of the centroacinar cell
marker Hes1. Importantly, Hes1 is also upregulated in human
PanIN lesions and pancreatic adenocarcinomas (Miyamoto et
al., 2003) and mouse PanIN lesions (Hingorani et al., 2003; see
discussion below). We acknowledge, however, that Hes1 ex-
pression per se does not necessarily reflect a centroacinar ori-
gin of metaplastic lesions; a formal proof will await direct lin-
eage tracing experiments.
The postnatal onset of metaplasia is consistent with a physi-
ologic trigger acting in concert with the genetic defect. The
basis for acinar cell death is unclear but may be related to a
“mass effect” of the expanding ductal system, leading to accu-
mulation of digestive enzymes in acinar lumens. Widespread
acinar cell death leading to expansion of duct-like epithelium
has also been described after surgical ligation of the pancreatic
duct (Scoggins et al., 2000). It is possible that acinar cells pro-
vide growth inhibitory signals that normally keep the ductal
compartment in check; loss of these signals upon acinar cell
death may accelerate the metaplastic process, accounting for
the increased proliferation rate detected in metaplastic lesions.
It is therefore tempting to speculate that this may be one
mechanism by which chronic pancreatitis elevates the risk of
pancreatic adenocarcinoma (Ghadirian et al., 2003).
Implications for pancreatic neoplasia
As one of the major effector arms of KRAS signaling, PI3-K is
well situated to play a role in pancreatic adenocarcinoma. The
downstream AKT kinase is activated in a large percentage of
human pancreatic tumors (Cheng et al., 1996; Ruggeri et al.,
1998; Altomare et al., 2003; Schlieman et al., 2003), and there
is evidence that reduced expression of Pten forms the basis of
pathway activation (Asano et al., 2004). Moreover, PI3-K sig-
naling is required for tumor cell growth in vitro (Bondar et al.,
2002; Shah et al., 2001; Perugini et al., 2000). Consistent with
these reports, genome-wide analyses of copy number alter-
ations point to common amplification or deletion of key com-
ponents in the PI3-K pathway (Aguirre et al., 2004 and data
not shown). Viewed in the context of these reports, our finding
that Pten deletion leads to ductal malignancies suggests that
PI3-K plays an important role in the natural history of pancre-
atic cancer.
Activation of a mutant Kras gene (KrasG12D) in the pancreas
leads to the development of premalignant PanIN lesions and
infrequent progression to pancreatic adenocarcinoma (Aguirre
et al., 2003; Hingorani et al., 2003). Further analysis of Pdx1-
Cre;LSL-KrasG12D mice suggests that the phenotypes resulting
from Kras activation and Pten deletion share several important
features. First, Hes1 expression is observed in the early PanIN
lesions of Pdx1-Cre;LSL-KrasG12D mice, raising the possibility192that these lesions may arise from centroacinar cells or duct
cells that express Hes1 (Figure S3; Hingorani et al., 2003). Sec-
ond, Pdx1-Cre;LSL-KrasG12D mice exhibit an activated PI3-K
pathway, as evidenced by the cytoplasmic relocalization of
FKHR (Figure S4). Third, the early lesions that arise in both
Pdx1-Cre;Ptenlox/lox and Pdx1-Cre;LSL-KrasG12D mice express
EGFR (Aguirre et al., 2003; Figure S5 and data not shown).
These similarities suggest that PI3-K activation and centroaci-
nar cell expansion may constitute common early events in pan-
creatic adenocarcinoma.
Nevertheless, there are marked differences between the phe-
notypes resulting from pancreatic Pten deletion and Kras acti-
vation. Specifically, activation of mutant KrasG12D results pre-
dominantly in ductal PanIN lesions with relative sparing of
acini. High-grade PanIN lesions occur almost exclusively after
5 months of age in KrasG12D mice (Hingorani et al., 2003), while
we frequently observe complete replacement of the Pten-defi-
cient acinar pancreas with metaplastic ductules prior to this
age. Several possible explanations may account for these dis-
crepancies. First, the Kras mutant phenotype may not be lim-
ited to ducts, as ductal metaplasia that is histologically similar
to that seen in Pten knockout animals also occurs in Pdx1-Cre;
LSL-KrasG12D mice (see, for example, Figure 1C in Aguirre et
al., 2003). In addition, the use of different methodologies cre-
ates a bias in the pools of cells that are susceptible to different
mutations. For example, expression of the LSL-KrasG12D locus
is under the control of the endogenous Kras promoter (Jackson
et al., 2001), and thus only those cell types that normally ex-
press Kras will express the mutant allele. To our knowledge,
the pancreatic expression pattern of the endogenous Kras
gene has not been investigated. In Pten-deficient mice, by con-
trast, cell types that normally express Pten will be most directly
influenced by its loss. Thus, variations in phenotypes may be
attributable to differences in the relative expression of Kras and
Pten within centroacinar and duct cells.
The rapid progression of ductal metaplasia in Pten-deficient
mice may further amplify these differences, as premature le-
thality prior to 5 months of age may preclude the emergence
of PanIN lesions that appear mostly later in the Kras model
(Hingorani et al., 2003). PTEN itself has functions that are inde-
pendent of its activity as an antagonist of PI3-K, which may
account for part of its pancreatic phenotype; among these is
the ability of PTEN to bind and modulate the DNA binding ac-
tivity of p53 (Freeman et al., 2003). Nevertheless, it remains
likely that other signaling surrogates that lie downstream of Ras
(such as Braf) may be necessary in addition to PI3-K for the
“full” oncogenic properties of KrasG12D. In particular, other Ras
signals may protect acinar cells from the apoptosis that occurs
in Pdx1-Cre;Ptenlox/lox mice, accounting for the greater ductal
specificity of the Pdx1-Cre;LSL-KrasG12D phenotype (Aguirre et
al., 2003).
The phenotype of Pdx1-Cre;Ptenlox/lox mice resembles that
of mice that misexpress TGFα in the exocrine pancreas (Sand-
gren et al., 1990; Jhappan et al., 1990). In both models, the
tubular complexes exhibit similar lobular distribution, histologic
appearance, expression of ductal markers, and Pdx1 expres-
sion. Moreover, tubular complexes become apparent predomi-
nantly in the postweaning period in both Pdx1-Cre;Ptenlox/lox
mice and TGFα transgenic mice. These phenotypic similarities
suggest that at least part of the TGFα signal, following Ras
activation, is mediated by PI3-K.CANCER CELL : SEPTEMBER 2005
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We have shown that PTEN is necessary to maintain the proper
balance of cell types within the pancreas. The expression of
Pdx1 by metaplastic ducts was unexpected, as Pdx1 expres-
sion is normally limited to islets in the adult pancreas. In the
embryo, Pdx1 is required for early steps in pancreas develop-
ment (Jonsson et al., 1994; Offield et al., 1996), and its expres-
sion marks a population of cells with the capacity to give rise
to all pancreatic lineages (Gu et al., 2002). PDX1 is expressed
by approximately 43% of human pancreatic cancers, and its
expression is correlated significantly with poor patient outcome
(Koizumi et al., 2003). Pdx1 is also expressed strongly in meta-
plastic ducts following TGFα misexpression (Song et al., 1999)
and weakly in the PanIN lesions of Pdx1-Cre;LSL-KrasG12D
mice (Hingorani et al., 2003). The expression of Pdx1 in this
array of premalignant lesions and cancers suggests that the
immature cell type marked by Pdx1 plays an important role in
pancreatic carcinogenesis. Together, these data are consistent
with a postulated association between developmental path-
ways and cancer (Meszoely et al., 2001). We did not detect an
increased number of Pdx1+ cells in Pten-deficient pancreata
prior to the onset of metaplasia. Pdx1+ cells within the meta-
plastic ducts are therefore likely to arise from the “reacquisi-
tion” of Pdx1 expression rather than the expansion of rare
Pdx1+ cells, although we cannot rule out the latter possibility.
Furthermore, the lack of metaplasia in Pdx1-CreERTM;
Ptenlox/lox mice (when injected postnatally with TM) argues
against a contribution of preexisting Pdx1+ cells to ductal
metaplasia.
Similarly, Notch signals are critical during embryonic devel-
opment for maintaining pancreatic progenitor cells in an undif-
ferentiated state (Murtaugh et al., 2003; Hald et al., 2003), but
Notch signaling is absent in most adult pancreatic cell types.
Normally, expression of the Notch target gene Hes1 is limited
to centroacinar cells and a subset of duct cells, but high levels
of Hes1 expression have been observed in PanINs and pancre-
atic cancers (Miyamoto et al., 2003). In this study, we found
Hes1 expression in the premalignant lesions of Pdx1-Cre;
Ptenlox/lox and Pdx1-Cre;LSL-KrasG12D mice, further support-
ing a role for Notch signaling during pancreatic carcinogenesis.
In the central nervous system, Pten regulates stem cell num-
ber (Groszer et al., 2001). It is possible that the Pdx1+ cells that
arise in the pancreata of Pdx1-Cre;Ptenlox/lox mice may retain
the capacity to give rise to multiple differentiated lineages un-
der appropriate conditions, and thereby act as multipotent pro-
genitor cells in the adult pancreas. Pten is irreversibly inacti-
vated through the action of Cre in our model, preventing us
from determining whether these cells retain the capacity to dif-
ferentiate upon withdrawal of the activated PI3-K signal. Mice
engineered to enable regulated activation and extinction of
PI3-K signaling will permit this hypothesis to be tested.
Experimental procedures
Mice
Mice were maintained in an SPF facility. The Elastase-CreERTM construct
was generated by fusing a 200 bp enhancer of the Elastase gene (gift of G.
Swift and R. MacDonald; Swift et al., 1989) to a minimal hsp68 promoter (a
gift from M. Gannon) and placing the chimeric promoter upstream of a
CreERTM coding sequence (a gift from A. McMahon). Transgenic mice were
generated by pronuclear injection. Two founders were identified that, when
crossed with Z/AP mice, showed acinar-specific expression of HPAP uponCANCER CELL : SEPTEMBER 2005TM injection. TM (Sigma; 20 mg/ml in corn oil) was injected intraperitoneally
twice per week into 4-week old mice (five injections of 8 mg each). Glucose
tolerance tests were performed by injecting 2 g/kg glucose intraperitoneally
after overnight fasting. BrdU (Amersham cell proliferation kit; RPN20) was
injected 2–3 hr prior to sacrifice. Ptenlox/lox, Ptenlox/D, Pdx1-Cre, and Pdx1-
CreERTM mice have been described (Groszer et al., 2001; Gu et al., 2002).
Z/AP mice were a gift from C. Lobe (Lobe et al., 1999). p53 mutant mice
(Jacks et al., 1994) and Z/EG mice (Novak et al., 2000) were obtained from
the Jackson Laboratory (Bar Harbor).
Histology
Formalin-fixed, paraffin-embedded 6–8 m sections of the pancreas were
used. The following primary antibodies were used: mouse anti-PTEN (Cell
Signaling; 1:50), rabbit anti-P-AKT (Cell Signaling; 1:500), mouse anti-BrdU
(Amersham cell proliferation kit), guinea pig anti-Pdx1 (a gift from Chris
Wright; 1:500), guinea pig anti-insulin (DAKO; 1:500), rabbit anti-glucagon
(Linco; 1:250), rabbit anti-amylase (Sigma; 1:500), rabbit anti-FKHR (Cell
Signaling; 1:50), rabbit anti-EGFR (Cell Signaling; 1:50), mouse anti-human
Muc5AC (Chemicon; 1:1000), rabbit anti-Muc2 (Santa Cruz; 1:150), and
rabbit anti-Hes1 (a gift from Tetsuo Sudo; 0.6 micrograms/ml). Biotinylated
DBA lectin (Vector) was used at 1:250 in HEPES/NaCl. TUNEL staining was
performed with the DeadEnd apoptosis detection kit (Promega) according
to the manufacturer’s instructions. Alcian blue staining was performed by
staining sections with 1% Alcian blue 8GX (Sigma) in 3% glacial acetic acid
for 30 min at room temperature (RT), followed by counterstaining with
nuclear fast red (Vector). For the detection of PTEN, P-AKT, BrdU, Pdx1,
and Hes1, antigen retrieval was performed by microwave heating the slides
in citrate buffer (pH 6) prior to staining. Secondary antibodies used were
from Jackson Immunoresearch. Staining for HPAP was performed as de-
scribed (Lobe et al., 1999; Gu et al., 2002).
For electron microscopy, mice were perfused with 2% glutaraldehyde in
0.1 M sodium cacodylate, rinsed in PBS, then embedded in EPON for mor-
phology. Blocks of tissue (0.1–1.5 mm3) were osmicated in 1% OsO4 in 0.1
M sodium cacodylate for 1 hr at RT, rinsed in cacodylate buffer, and then
rinsed in distilled water before staining in 2% uranyl acetate/DDW for 1 hr.
Sections were dehydrated in graded alcohols and placed in 100% propyl-
ene oxide. The blocks were infiltrated in EPON:PO 1:1 overnight at RT, then
changed to 100% EPON and polymerized overnight. Sections (90 nm) were
cut on a Reichert-Jung Ultracut E microtome, collected on slot grids, and
stained with 2% urinal acetate and lead citrate before viewing on a Philips
CM 10 electron microscope.
Supplemental data
The Supplemental Data include six figures and can be found with this article
online at http://www.cancercell.org/cgi/content/full/8/3/185/DC1/.
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